Almac’s Radiolabelling services: enhancing drug development efficiency and regulatory compliance
Almac provides a streamlined approach for pharma companies to meet the Radiolabelling requirements of Phase 1 to 3 clinical trials, signaling our intent to meet the high-quality service needs of the sector. Our capability to provide cGMP services for final drug candidates, peptides, small molecules, and advanced intermediates effectively answers the demands of the market.
Read our latest Almac Voice from Dr. Sean Kitson, Investigator of Radiochemistry, to find out more on Almac’s Radiolabelling and stable isotope labelling services for pharmaceutical companies and CROs.View Resource
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.